Summary: Single cells from mammary carcinoma infiltrating bone marrow can be detected in marrow aspirates using immunocytochemical stains for epithelial membrane antigen (EMA). This technique has been used to examine marrow aspirates taken from multiple sites from 24 patients at surgery for breast cancer. Ten of these patients had EMA-positive cells in their marrow, while 32 marrow samples from patients who did not have carcinoma were negative. These results have been combined with those obtained by taking aspirates from single sites from 47 breast patients without known skeletal deposits.
Introduction
Antisera to a component of the cell surface called epithelial membrane antigen (EMA) (Heyderman et al. 1979) can be used in immunohistochemical techniques to visualize metastatic cells in aspirates of bone marrow from patients with mammary carcinoma (Sloane et al. 1980 , Dearnaley et al. 1981 . EMA is confined to, but widely distributed in, epithelial tissues and tumours derived from them; in particular, it is found almost invariably in carcinomas of the breast and their metastases . It is generally absent from normal and neoplastic haemopoietic, lymphoid, osseous and other connective tissues. Immunohistochemical stain for the antigen picks out micrometastases which might not be recognized by conventional stains. For example, in a study of histological sections of marrow aspirates, out of 73 samples which were negative by conventional methods, 9 contained EMA-positive cells (Sloane et al. 1980) .
In order to reduce the sampling error introduced by taking a section from a block of tissue; we developed a technique for staining smears of bone marrow aspirates. EMApositive cells were found in the single aspirates from 21 (representing 30%) of the patients studied; in only 11 of these were malignant cells detected by conventional stains (Dearnaley et al. 1981) . Of particular interest was the observation that EMA-positive cells were found in 2 of the 20 samples taken from patients who had primary breast cancer with no other evidence of metastasis.
In the latter study, the assumption that the EMA-positive cells were malignant mammary cells was supported by the observations that they had cytological features entirely consistent with metastatic carcinoma; that patients with known skeletal metastases had a higher incidence of EMA-positive cells in their marrow; that EMA-positive cells were found in the 'Based on paper read to Section of Oncology, 14 April 1982. Accepted 15 December 1982 2Correspondence to DPD at The Haddow Laboratories. Clifton Avenue. Sutton. Surrey SM2 5PX highest numbers in those marrows shown to contain malignant cells by conventional techniques; and that patients without any other evidence of metastases had few EMApositive cells in their marrow.
We have now extended this study by examining multiple aspirates taken from 24 patients at the time of surgery for breast cancer and 32 marrow samples from patients who were being treated for conditions other than carcinoma.
The objectives were to discover whether significant numbers of primary patients exhibited EMA-positive cells in their marrow, to assess the improvement in the rate of pick-up afforded by taking aspirates from several sites, and to gain more information about the prognostic significance of the presence of EMA-positive cells. To assist in the last objective, the data in the follow up of the patients in this study were combined with those from 47 patients (primary and follow up but without known skeletal deposits) who had aspirates taken from single sites in our earlier study (Dearnaley et al. 1981) .
Patients and methods Twenty-four patients had multiple aspirates taken immediately prior to surgery for breast cancer. Patients considered to have a poor prognosis (clinically axillary lymph node positive) were chosen if available. Twenty-two patients were having surgery for the primary tumour and 17 of those had no evidence of distant metastases (see Table 2 ). While the patients were under general anaesthesia, aspirates were taken from six sites (sternum x 2; anterior and posterior iliac crest bilaterally), together with a trephine biopsy from the right posterior iliac crest. Additionally 15 ml peripheral blood was taken from an antecubital vein.
Single aspirates of marrow were taken from the posterior iliac crest of 68 patients, 47 of whom had no clinically detectable bone metastases. The majority of these were in the previously reported study (Dearnaley et al. 1981) ; 17 of them were having a primary tumour removed, the remainder were being examined as part of the procedure for follow up (see Table I ).
Informed consent was obtained from all patients. All the breast cancer patients were staged as described previously . Bone metastases were diagnosed after radiological skeletal survey and isotope bone scan using 99mtechnetium diphosphonate. Samples of bone marrow from 32 people without evidence of epithelial malignancy were also examined. Thirteen of these were from normal donors giving marrow for transplantations; 9 were taken from patients having marrow autografts prior to high-dose chemotherapy (7 melanoma, I chronic granulocytic leukaemia, I neuroblastoma); 3 were from patients shown at subsequent biopsy to have benign breast disease; one from a patient with iron deficiency anaemia; 3 from patients with acute myeloid leukaemia; 2 from patients with non-Hodgkin's lymphoma; and the remaining patient had melanoma.
Four air-dried smears were made from each aspirate for routine cytological examination; the remainder of the sample (0.5-2 ml) was placed in 5 ml heparinized medium. Erythrocytes were removed on FicolljHypaque prior to washing and smearing and wet-fixing the cells in ethanol, as described previously (Dearnaley et al. 1981) .
The smears were stained using a rabbit antiserum raised against human milk fat globule membranes and absorbed to render it specific for EMA (Heyderman et al. 1979 . The second antibody was affinity-purified sheep anti-rabbit conjugated to alkaline phosphatase. The detailed procedure has been described previously (Dearnaley et af. 1981) .
Two types of control were used. Firstly, antiserum absorbed with a purified preparation of EMA (Ormerod, Steele, Westwood and Mazzini, in preparation) was applied to smears from 30 aspirates. No staining was observed. In the second, the 32 aspirates from patients without epithelial malignancies were stained for EMA. In a minority of these smears, three types of reaction were seen. Firstly, very rarely, a weak membrane stain was found on some myeloid cells (metamyelocyte and earlier). These cells could be identified by their characteristic nuclear size and shape, high nuclear-cytoplasmic ratio and lack of pleomorphism. Secondly, in some patients a few plasma cells stained but again they could easily be identified morphologically. Finally some degenerate cells showed irregular staining for EMA.
In contrast, single cells which were classified as malignant were stained strongly for EMA both in the cytoplasm and the plasma membrane (see Figure I ) and had the morphological characteristics of malignant cells: nuclear size was greater than or similar to that of a normal marrow blast cell but the nuclear cytoplasmic ratio was lower; nuclear pleomorphism and hyperchromatism were present and nucleoli were often prominent. Such cells showed considerable variation in size but were larger than normal marrow blast cells. In some preparations there were stained cells whose morphology was obscured by overlying cells or whose staining pattern was atypical; in the absence of other EM A-positive cells, such aspirates were recorded as suspicious.
We had previously failed to note the weak staining of a minority of plasma and early myeloid cells in a few patients (Sloane et al. 1980 . Alcohol fixation of smears appears to preserve EMA in these cells better than formalin fixation and paraffin embedding, and this probably accounts for the difference. A careful study of this phenomenon, including the use of monoclonal antibodies raised against milk fat globule membranes (Foster et al. 1982) , has shown that this is due to the weak expression of a determinant of the epithelial membrane antigen by these cells and not due to an impurity antibody (Dearnaley, unpublished work) .
Results Table I shows the results obtained on the aspirates of marrow taken from a single site in the posterior iliac crest. Table 2 , shows the more recent data on aspirates from multiple sites.. There are fewer patients in this group because of the longer time needed to accumulate patients. The 
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• Previously treated with radiotherapy for painful collapse of a lumbar vertebra; no evidence of disease when aspirated.
aspirates could only be taken from patients under general anaesthesia prior to surgery and the increase in the number of samples per patient meant that more smears per patient had to be stained and read.
Sections of the primary tumours from these patients were also stained. They all showed a strong reaction for EMA with the exception of one tumour in which the staining was weak and patchy, When present, sections of lymph node metastases were stained: they were all EMA-positive.
Comparison of the number of positive or suspicious cells found at each site of aspiration (Table 3) showed that two aspirates, one from each side of the posterior iliac crest, would have picked up 8 of the 10 positive/suspicious cases. A single aspirate would have picked up only half the number. In one patient one suspicious cell was found in the right anterior iliac crest only, and in a second patient one suspicious cell was found in the lower sternum only. Two of the twenty-four patients from whom we took multiple aspirates had tumour cells in the trephine biopsies: these cases had either skin infiltration or local recurrence and showed EMA-positive cells on the marrow smears; one of these was the only aspirate in this series which was positive by conventional cytology. Neither patient had skeletal metastases diagnosed on skeletal surveyor bone scan. No EMA-positive cells were found in the peripheral blood of any of the patients from whom multiple aspirates of marrow were taken. The time of development of bone metastases visible on skeletal radiography or technetium bone scan was recorded for the 68 patients (47 single plus 21 multiple aspirate patients) who had no evidence of bone metastases at the time of aspiration. The relationship of EMA status to survival without bone metastases was examined by calculating Kaplan-Meier curves (Peto et al. 1977) . Figure 2 shows the patterns of bone metastases-free survival with 95% confidence interval for patients with EMA-positive/suspicious cells and for patients with EMA-negative cells. The logrank test, used to compare the patterns in the two groups, gave a P value of 0.0002. There is thus strong evidence to suggest that EMA-negative patients have a higher probability of bone metastases-free survival than patients with EMApositive/suspicious cells. It should be stressed that 26 of these patients (16 EMA-negative, 10 EMA-positive) had locally recurrent disease or metastases at other sites at the time of aspiration.' Again combining data from the two studies, there were 34 primary breast cancer patients (25 EMA-negative, 9 EM A-positive) who were free of clinically detectable. distant metastases at the time of aspiration. To date, 5 of the 9 EMA-positive patients have developed recurrent disease, compared with only one of the 25 EMA-negative patients.
There were no E'MA-positive cells detected in any of the samples of marrow from 32 patients who had no evidence of epithelial malignancy. The difference between this group and the 34 primary patients referred to above with regard to the detection of EMA-positive cells is significant, with P< 0.001.
Discussion
We have recorded cells in the bone marrow of patients with breast cancer on the basis of a combination of expression of EMA and the morphological characteristics of malignancy. Our previous work (Dearnaley et al. 1981) has established that there are strong grounds for assuming that these cells are indeed metastatic carcinoma cells. This assumption has been reinforced by the failure to record such cells in samples of marrow from 32 patients without carcinoma.
The results on the multiple aspirates of marrow have shown that increasing the number of sites of sampling from one to six approximately doubles the rate of detection (Table 3 ). In view of this result, in the series of patients now being studied, we have increased the number of sites to eight by including a further two from the sacrum.
. At this stage the data on the follow up can only be preliminary, but they do indicate a strong correlation between the presence of EMA-positive cells in the marrow and the subsequent development of bone metastases. The data do not establish that EMA is necessarily an independent prognostic factor because the two populations were different in other respects at the time of aspiration -the EMA-positive group contained more patients with visceral rather than locally recurrent disease and more primary patients categorized as poor-risk with respect to lymph node status and tumour size.
The number of primary patients evaluated so far remains small. However, the initial follow up suggests that EM A-positive patients fare particularly badly. The samples from these patients usually contained small numbers of isolated single cells rather than tumour clumps. Such EMA-positive cells cannot represent established metastases. It is possible that they are an indication of a carcinoma's metastatic potential, showing a capability to seed cells into the marrow sinus; some of these cells may then have the capacity to form viable tumour deposits.
We are now recording results from a larger number of unselected primary breast cancer patients with a view to discovering whether: (a) the observed strong correlation between EMA-positive cells in the marrow and the subsequent development of bone metastases will continue to hold for a larger series of primary patients; (b) the presence of these cells identifies a set of primary patients at high risk; and (c) this gives a better prognostic indicator than an index based on lymph node status, tumour size and either tumour grade or hormone receptor status (Haybittle et al. 1982) .
